Sign In
Buy WINT
$0.0140
+0.0004 (+2.94%)
At Close: Jun 03, 2026
CommLoan Achieves Nationwide Regulatory Approval Across All 50 States
08:02am, Tuesday, 17'th Mar 2026
Company plans reverse merger with Windtree Therapeutics as it expands its AI-powered commercial lending marketplace SCOTTSDALE, Ariz., March 17, 2026 /PRNewswire/ -- CommLoan, a commercial real estat
Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree t
Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree t
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update
01:35am, Monday, 03'rd Nov 2025
Windtree Therapeutics, Inc. (NASDAQ: WINT - Get Free Report) was the recipient of a large decrease in short interest in October. As of October 15th, there was short interest totaling 218,900 shares, a
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
09:00am, Monday, 11'th Aug 2025
Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
09:01am, Tuesday, 29'th Jul 2025
Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in out
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy
09:00am, Thursday, 24'th Jul 2025
Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July 24
Windtree expected to become a leader and the first NASDAQ-listed company offering direct exposure to the Binance Smart Chain Ecosystem (BNB) Windtree expected to become a leader and the first NASDAQ-l
Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure
09:00am, Wednesday, 02'nd Jul 2025
1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel
04:05pm, Thursday, 26'th Jun 2025
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 20
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime
ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and rep
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
08:18am, Tuesday, 06'th May 2025
If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until 20
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
08:47am, Wednesday, 26'th Mar 2025
-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
08:00am, Monday, 24'th Mar 2025
WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating
